Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on De protection. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel esterification and deprotection technology for candesartan cilexetil intermediates. High yield, mild conditions, suitable for large-scale pharmaceutical manufacturing.
Patent CN1708504A reveals a streamlined synthesis for 1β-methylcarbapenem intermediates, offering cost reduction and improved supply chain reliability for pharmaceutical manufacturers.
Novel semi-synthetic route for taxane intermediates ensuring >99% purity and scalable docetaxel production without hazardous reagents.
Novel acid-catalyzed deprotection method for OSW-1 synthesis eliminates palladium residues, ensuring high purity and cost reduction in pharmaceutical intermediate manufacturing.
Patent CN118459469A details a novel Mitsunobu route for Ibrutinib. Achieves 99.95% purity with water-soluble byproducts, ensuring cost reduction and supply reliability.
Patent CN102212060A details a novel aminolysis route for Lafutidine, eliminating dihydro impurities and offering significant cost reduction in pharmaceutical manufacturing.
Patent CN102786498A details a novel Repaglinide synthesis using CDI coupling and optimized deprotection, offering significant cost reduction and scalability for API manufacturing.
Patent CN107778349A details a low-cost GHK acetate synthesis. Trt protection ensures purity and eliminates TFA, offering supply chain advantages.
Novel patent CN119191963A enables high-yield synthesis of 5-formyl-2-4-dimethylbenzoic acid. Reduces costs and improves supply chain reliability for pharmaceutical intermediates.
Patent CN109206465A reveals a two-step synthesis for Adenosine Cyclophosphate offering reduced solvent use and high purity for reliable pharmaceutical intermediates supply chains.
Patent CN113461773A reveals a high-yield liquid phase route for LKP tripeptide. Discover cost-effective manufacturing strategies for ACE inhibitory peptides.
Patent CN114213503A details a novel phthaloyl-based liquid phase synthesis for snake venom tripeptide, offering significant cost reduction and eliminating heavy metal catalysts for cosmetic manufacturers.
Novel synthesis route avoids palladium catalysts ensuring high purity and supply chain stability for alopecia areata treatment intermediates globally
Discover the novel Alloc-protected solid-phase synthesis of Somatostatin KE108. Eliminating hydrogen hazards for safer, scalable pharmaceutical intermediate production.
Patent CN112538103B reveals a safer, hydrogen-free synthesis route for Somatostatin KE108 using Alloc protection, offering significant cost reduction in peptide manufacturing.
Patent CN1113885C details a novel aluminum halide method for deprotecting beta-lactams, offering high yields and recyclable protecting groups for cost-effective API manufacturing.
Patent CN1134446C reveals a high-yield deprotection method for cefdinir intermediates using perhalic acid, offering significant cost reduction in antibiotic manufacturing.
Patent CN1126754C reveals a novel one-pot synthesis for 3-cephem antibiotics, offering significant cost reduction and improved stability for API manufacturing supply chains.
Patent CN106478492B reveals a mild synthesis route for high-purity phenolic compounds. This method offers significant supply chain stability and cost reduction potential for global buyers.
Patent CN106892832B details a high-purity Sitagliptin impurity synthesis. This method offers significant cost reduction in pharma manufacturing and reliable supply chain continuity.